Medpacto Inc.
South‑Korean drug discovery firm MedPacto is advancing a cancer & autoimmune pipeline—ME‑1601mAb (BSP1), MS‑1601A (TRG1), and vactosertib—targeting unmet needs in a fast‑growing specialty pharma market.
Headquarters: South Korea (KOR)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical and Diagnostic Laboratories
- HQ: Seoul
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.